



Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

12 May 2023

The Manager Companies
ASX Limited
20 Bridge Street
SYDNEY NSW 2000

(2 pages by email)

Dear Madam,

SECOND SITE APPROVED FOR PHASE 2 COVID-19 TRIAL


The Directors of Biotron Limited ('Biotron' or 'the Company') (ASX: BIT) are pleased to announce that the Company's Phase 2 COVID-19 trial with its lead antiviral drug BIT225 has extended to include a second trial site in Thailand, following receipt of approval from the Khon Kaen University Ethics Committee for Human Research.

As previously advised (ASX announcement 4 May 2023 contained details of the trial), Biotron has commenced a Phase 2, double blind, placebo-controlled clinical trial (BIT225-012) to determine if 7 days of treatment with BIT225 commenced within 3 days of onset of COVID-19 symptoms results in reduction in SARS-CoV-2 blood viral load, clinically favourable changes in viral, inflammatory and immune activation markers, as well as improvement in clinical symptoms of COVID-19.

Biotron's Managing Director, Dr Michelle Miller said, "Much effort and thoughtful consideration has been put into the design and implementation of this important Phase 2 COVID-19 trial. There remains a need for new, effective oral drugs to treat infection and prevent severe disease.

BIT225 has an established safety profile in human trials, and animal studies have shown it to have both antiviral and immune modulatory activity against SARS-CoV-2. It has the potential to be an important first-in-class drug for COVID-19 treatment. We are now focused on enrolment and dosing with the aim of completing the trial as quickly as possible."

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn11682

This announcement has been approved by the Company's Managing Director.

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and COVID-19, and additional promising preclinical programs including HBV. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Coronavirus, Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.

Enquiries

Dr Michelle Miller
Managing Director
Biotron Limited
+61-(0)412313329

mmiller@biotron.com.au

Rudi Michelson
Monsoon Communications
+61-3 9620 3333